Breast Conserving Therapy (BCT)
Worldwide over 1 million women diagnosed with breast cancer undergo BCT (surgery with follow-up radiotherapy) annually as an alternative to mastectomy, whereby both procedures result in comparable survival rate for early breast cancer.
BCT Recurrence
The current standard of care recommending BCT suffers up to 15% recurrence rate within 10 years due to positive margin (residual cancer cells in the tumor bed after solid tumor removed).
Breast Cancer Survival
5-years residual risks of recurrence for patients with stage I, II, III and IV cancers are about 7%, 11%, 13% and >20% respectively, relating to 5-years survival rate of 100%, 93%, 72% and 22% respectively.
10
Number of peer-reviewed scientific papers
9
Number of projects completed
2
Number of patents and patent pending
27
Number of conferences
TEAM
Valérie Léveillé, Eng., M. Eng., PhD
CEO / Founder
Valérie has 16-yr experience in technology R&D, design and commercialization. She is co-inventor of NexPlasmaGenTMs technology.
Audrey Glory, PhD
Preclinical trials leader
Audrey has 5-yr experience in conducting preclinical trials for breast and other cancers. She works at NexPlasmaGen and at the CR-CHUM.
Philip Wong, MDCM, MSc, FRCPC
Medical Advisor
Philip is an Assistant Professor at the Department of Radiation Oncology, University of Toronto. He is a clinician-investigator at the CR-CHUM. He leads NexPlasmaGen’s clinical program and is co-inventor of NexPlasmaGen’s technology.
Julie Lafontaine, PhD
Laboratory supervisor, CR-CHUM
Julie has 7-yr experience supervising Dr. Wong’s laboratory and plays a crucial role in NexPlasmaGen preclinical trials. She works at the CR-CHUM.
BOARD DIRECTORS
Valérie Léveillé, Eng., M. Eng., PhD
Board member and CEO
David Uffer, M.A., MBA
Managing Director MedTech, Trinity Life Sciences
30 years commercializing medical devices
Past: VP Medtech General Inception, BD Director, Covidien (now Medtronic) Hologic, Boston Scientific, VP at Bovie Medical
SCIENTIFIC ADVISORY COMMITTEE
Philip Wong
MDCM, MSc, FRCPC
Associate Professor, Department of Radiation Oncology, University of Toronto
Clinician-investigator-Princess Margaret Cancer Centre
Louis Gaboury
M.D., Ph.D., FRCP(C)
IRIC Histology Platform Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal Anatomic-Pathologist, CHUM
Erica Patocskai
MD, FRCSC
Chief, Surgical Oncology Service, CHUM
Associate clinical professor, Department of Surgery, Faculty of Medicine, University of Montreal
Jean-François Lapointe
Ph.D.
Consultant, Regulatory and Clinical Affairs
Lok North-America
BUSINESS ADVISORY COMMITTEE
David Uffer
MBA, B.A.
Managing Director MedTech, Trinity Life Sciences
30 years commercializing medical devices
Past: VP Medtech General Inception, BD Director, Covidien (now Medtronic) Hologic, Boston Scientific, VP at Bovie Medical
Sohaib Siddiqui
B.ScH, MD, FRCSI
EIR @ TIAP & Faculty of Medicine
Innovation Fellow at Women’s College
Managing Partner, Kettlebeck Ventures
Edward J. Dougherty
B.A., M.S., Th.M.
Principal at dougherty.consulting, llc,
30 years in regulatory and reimbursement for medical devices
Samuel Ohayon
B.S., M.S.
Entrepreneur in Residence at CTS
Venture Partner for Health Tech funds
Health Tech Executive
Biotech Entrepreneur
Trained as a Molecular Pathologists
See our partners who support the company and our technology development
Supported in part by advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
